Scarica l'app Stockscreener
0.5056
7.23%
-0.0394
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.545
Aprire:
$0.48
Volume 24 ore:
3.30M
Relative Volume:
1.26
Capitalizzazione di mercato:
$19.97M
Reddito:
$875.70K
Utile/perdita netta:
$-39.57M
Rapporto P/E:
-0.3767
EPS:
-1.3423
Flusso di cassa netto:
$-33.65M
1 W Prestazione:
-10.23%
1M Prestazione:
-26.25%
6M Prestazione:
-82.74%
1 anno Prestazione:
-82.26%
Intervallo 1D:
$0.43
$0.5245
Intervallo di 1 settimana:
$0.43
$0.5992
Portata 52W:
$0.43
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Nome
Vistagen Therapeutics Inc
Settore
Industria
Telefono
650-577-3600
Indirizzo
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.5056 | 21.53M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Downgrade | Maxim Group | Buy → Hold |
| 2025-12-17 | Downgrade | Stifel | Buy → Hold |
| 2025-12-17 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-07 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-07-22 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Iniziato | Robert W. Baird | Outperform |
| 2021-02-18 | Iniziato | Jefferies | Buy |
| 2021-01-04 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Iniziato | Maxim Group | Buy |
| 2018-02-08 | Reiterato | Chardan Capital Markets | Buy |
| 2017-03-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2026 Earnings Call Transcript - Insider Monkey
VTGN Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - marketscreener.com
VTGN SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - GlobeNewswire Inc.
High-Risk Warning: Analyst Flags Significant Uncertainties for Vistagen Therapeutics Investors - TipRanks
Vistagen Therapeutics Balances Progress and Uncertainty - TipRanks
VTGN Investors with Large Losses Should Contact Robbins LLP - GlobeNewswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Vistagen Therapeutics Inc (VTGN) Q3 2026 Earnings Call Highlight - GuruFocus
Earnings call transcript: VistaGen Therapeutics Q3 2026 highlights AI-driven trial analysis - Investing.com Canada
Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update - BioSpace
VistaGen (VTGN) Q3 2026 Earnings Call Transcript - The Globe and Mail
What is Vistagen Therapeutics Inc.’s valuation compared to sectorQuarterly Market Review & Long-Term Capital Growth Strategies - mfd.ru
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN) - ACCESS Newswire
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates - Bitget
Vistagen (VTGN) Surpasses Revenue Expectations in Q3 - GuruFocus
Vistagen Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
R&D-driven loss at Vistagen (Nasdaq: VTGN) as PALISADE-4 Phase 3 advances - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesVTGN - PR Newswire
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ... - bdtonline.com
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER - GlobeNewswire
The Gross Law Firm Notifies Vistagen Therapeutics, Inc. Investors of a Class Action Lawsuit and ... - bdtonline.com
The Gross Law Firm Notifies Vistagen Therapeutics, Inc. - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Vistagen - GlobeNewswire
Investors who lost money with shares of Vistagen Therapeutics, - openPR.com
VTGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - The Malaysian Reserve
LEVI & KORSINSKY, LLP ANNOUNCES SECURITIES CLASS ACTION FILED AGAINST VISTAGEN THERAPEUTICS UNDER FEDERAL SECURITIES LAWS - PR Newswire
Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2026 Result - GuruFocus
Gap Down: Will Vistagen Therapeutics Inc outperform during market ralliesJuly 2025 Weekly Recap & Daily Momentum Trading Reports - baoquankhu1.vn
How Vistagen Therapeutics Inc. stock performs after earnings2025 Analyst Calls & Breakout Confirmation Alerts - mfd.ru
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Vistagen Therapeutics, Inc. to Contact the Firm Today! - ACCESS Newswire
2026-02-10 | VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Vistagen Therapeutics, Inc. to Contact the Firm Today! | NDAQ:VTGN | Press Release - Stockhouse
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics - TMX Newsfile
Bronstein, Gewirtz & Grossman LLC Urges Vistagen - GlobeNewswire
Vistagen Therapeutics Securities Litigation: When Clinical Optimism Meets Disclosure Duty - TipRanks
VistaGen’s PALISADE-3 trial fails primary endpoint in SAD - MSN
VistaGen Receives Nasdaq Notice on Minimum Bid Compliance - TipRanks
Vistagen Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VTGN Investors Encouraged to Seek Lead Plaintiff Role in - GlobeNewswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - accessnewswire.com
VTGN Investor Alert: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline on March 16, 2026 - PR Newswire
ROSEN, A LONGSTANDING LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics - marketscreener.com
Investors who lost money on Vistagen Therapeutics, Inc.(VTGN) should contact The Gross Law Firm about pending Class ActionVTGN - ChartMill
VTGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
March 16, 2026 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTGN - The Malaysian Reserve
VTGN INVESTOR ALERTLEVI & KORSINSKY, LLP ANNOUNCES CLASS ACTION OVER ALLEGED MISLEADING STATEMENTS ABOUT CLINICAL TRIAL PROGRESS - The Malaysian Reserve
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, I - GuruFocus
Vistagen Therapeutics Inc Azioni (VTGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):